Lexiscan: Clinical Trials

5 trials of Lexiscan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 unknown. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 4, Unknown 1

Follow Lexiscan: new trials by email Literature Review of Lexiscan trials Research Report on Lexiscan

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) - Coronary Artery Disease (CAD)
Phase 3CompletedAstellas Pharma Global Development, Inc.11472012-06-012016-02-08
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
regadenoson, overencapsulated caffeine, technetium - Coronary Artery Disease (CAD)
Phase 3CompletedAstellas Pharma Inc3472009-03-242024-12-03
Myocardial Perfusion Assessment With Multidetector Computed Tomography
Regadenoson (Lexiscan) [muti-detector computed tomography] - Coronary Artery Disease
Phase 3UnknownTennessee Heart and Vascular Institute, P.C.1002009-02-012009-02-18
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Regadenoson, Adenosine - Coronary Artery Disease
Phase 3CompletedGilead Sciences7872004-04-012009-11-26
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Regadenoson, Adenosine - Coronary Artery Disease
Phase 3CompletedGilead Sciences12312003-10-012009-11-26

Conditions studied

Coronary Artery Disease (5)  ·  Ischemia (1)

Sponsors

Gilead Sciences (2)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Inc (1)  ·  Tennessee Heart and Vascular Institute, P.C. (1)

Countries

United States (5)  ·  Argentina (1)  ·  Peru (1)  ·  Puerto Rico (1)

Results publications

PMID 17826318, PMID 21082298, PMID 28224449